News & Events
Published On: 1/10/2019
TARGET PharmaSolutions to advance NASH Research through new collaboration
TARGET PharmaSolutions, Inc., a real-world data solutions company, is pleased to announce that Novartis has entered into a long-term strategic alliance for TARGET-NASH.
TARGET-NASH is a longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH will enroll up to 15,000 patients over the coming years. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).
Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited to have Novartis join TARGET-NASH. TARGET-NASH has enrolled a large, diverse patient population and is generating valuable real-world data and insight on NASH, including the natural history of the disease and current treatment patterns. The TARGET real-world data solution which includes a biorepository and patient reported outcomes is a critical resource for our collaborators as they work to better understand and to combat this rapidly growing disease.”
TARGET PharmaSolutions provides insights and actions to improve clinical, medical, and commercial outcomes throughout the pharmaceutical development and commercialization process. The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. This model enables TARGET’s stakeholders to answer critical strategic and planning questions. The TARGET model also provides its stakeholders access to a biorepository linked to validated clinical outcomes, including patient reported outcomes.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
01/15/2021Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
12/21/2020TARGET-HCC Initial Manuscript Published in Hepatology Communications
12/18/2020Target RWE Virtual Posters at Annual AIBD, RAD Conferences
11/28/2020TARGET-DERM Objectives Published in BMJ Open
11/13/2020Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities